BioMarin Pharmaceutical Inc. started first-in-human testing of a drug for achondroplasia, the most common form of human dwarfism.
Novato-based BioMarin (NASDAQ: BMRN) said it started the Phase I safety and tolerability study of BMN-111 in 74 healthy volunteers. It expects to report results from the trial in the third quarter.
No comments:
Post a Comment